Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors a...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CYTK Stock News
Cytokinetics (CYTK) Could Be 22% Undervalued On Its Growth Narrative
Cytokinetics CEO Robert I. Blum disposes of 7,500 common shares for $615,150
How Myqorzo’s US and German Launches Will Impact Cytokinetics (CYTK) Investors
Cytokinetics, Incorporated Stock 12‑Month Price Target Raised to $108.47, Implies 26% Upside
High-Profile Insider Trade Shakes Up Cytokinetics Watchlist